1. Introduction {#s0005}
===============

Diabetic retinopathy (DR) is a prolonged hurdle occurring in diabetic patients due to an uncontrolled increase in blood glucose level and, if untreated, leads to visual impairment ([@b0075]). Several mechanisms are involved in DR viz., microvascular damage, pro-inflammatory cytokines upregulation, generation of ROS, as well as increased VEGF expression are engaged in development of DR ([@b0070], [@b0055]). Besides, high production of polyol (sugar alcohol) in addition to AGEs is the main culprits in the pathogenesis of DR ([@b0040]). On the other hand, PKC is activated by DAG which is involved in various cellular functions as a microchip in cell signalling ([@b0155]). Beta isoform of this kinase protein is known as PKC *β* aid in the development of DR. Activation of PKC *β* by DAG has been demonstrated in the retina of hyperglycaemic animals, results in microvascular damage in the retina ([@b0080]) which may be due to high generation of ROS via PKC pathway.

Further, activation of certain enzymes (NADPH oxidase and xanthine oxidase) decreases antioxidant guard and increases ROS oppression ([@b0015]) which worsen the state of retina in DR. Henceforth, the utilization of antioxidants can be beneficial for the treatment of DR.

Morin (2′,3′,4′,5,7-pentahydroxyflavon) is a dietary bioflavonoid, initially obtained from the individuals of Moraceae family plants ([@b0125]). Much evidence has confirmed that Morin has beneficial effects on several diseases. It has demonstrated to be effective against a wide range of pathological conditions. Besides many biological effects, morin exerts potent antidiabetic ([@b0005], [@b0020], [@b0025]) and antioxidants ([@b0100], [@b0145]) activities. Thus, in this experimental work, an attempt was taken to examine the effect of morin in STZ persuade DR in rats.

2. Methodology {#s0010}
==============

2.1. Drug and chemicals {#s0015}
-----------------------

Blood glucose, TNF-*α*, IL1-β, and VEGF kits were purchased from Sigma-Aldrich, USA. Every other chemical for this present evaluation was a commercial product of analytical reagent grade.

2.2. Animals {#s0020}
------------

Normal healthy Albino Wistar rats (male), body weight ranges from 180 to 200 g, were selected for the study. They were kept in cages made up of polypropylene on a 12 h day and 12 h night cycle. The temperature was maintained at 22 ± 1 ^ο^C. Acclimatization of animals was done for 7 days prior to the commencement of experiment. Standard pellet diet was supplied with fresh drinking water ad libitum to the animals. Animal Ethics Committee of Jinshan Hospital of Fudan University (Ethics Number: FDJS201900769) approved this experiment.

2.3. Experimental design {#s0025}
------------------------

A single dose of STZ (60 mg/kg; i.p.) was used to induce diabetes in the animals. STZ solution prepared by diluting with freshly prepared citrate buffer (0.1 M) with maintained pH 4.5. 48 h after STZ injection tail vein blood was collected to estimate BGL. Animals with blood glucose concentration 200 mg/dl or more was considered in this experiment.

Wistar rats were alienated into 5 groups (n = 6).

Group I -- Normal control (saline solution- 0.5 ml/100 g).

Group II -- Diabetic control (saline solution- 0.5 ml/100 g).

Group III -- Morin (25 mg/kg).

Group IV -- Morin (50 mg/kg)

Group V -- Metformin (350 mg/kg)

All the animals underwent the treatment for 60 days as mentioned above. Blood glucose of fasting animals of group I-V were determine on day 0, 7th, 30th, and 60th ([@b0005], [@b0020], [@b0025]).

2.4. Endogenous antioxidants, pro-inflammatory cytokines and VEGF content in retina {#s0030}
-----------------------------------------------------------------------------------

Retinal tissue homogenate (10%w/v) was prepared using trisphosphate buffer (50 mM), and the pH maintained at 7.4. Then centrifugation of the tissue homogenate was done for 10 min at 4 ^ο^C. The obtained supernatant was used to determine LPO ([@b0090]), GPx ([@b0105]), CAT ([@b0115]), and SOD ([@b0085]). TNF-*α*, IL-1*β*, and VEGF estimation were performed as per the instruction of the manufacturer.

2.5. Morphometric study {#s0035}
-----------------------

A morphometric computer-assisted image analysis technique was used for morphometric study of the retinal tissue section. For this purpose, Image J software was used as per the instructions of Jiang and co-researchers' published article ([@b0065]).

2.6. Statistical design/study {#s0040}
-----------------------------

Obtained results were displayed as mean ± standard error from 6 animals in each group. Further a one-way analysis of variance was used followed by Tukey Multiple Comparison Test using the latest graph pad prism software. P \< 0.05 was considered statistically significant.

3. Results {#s0045}
==========

3.1. Blood glucose level {#s0050}
------------------------

It is well known that STZ utilize GLUT2 and enter into the *β*-cells. After entering into the *β*-cells it alkylates the DNA causes damage or death of *β*-cells. This condition decreases the synthesis or production of insulin results increase in glucose level in the plasma. From [Table 1](#t0005){ref-type="table"}, we can interpret that diabetic animals of 2nd group (group II) showed a noteworthy or significant elevation of blood glucose levels on 7, 30, and 60 days. Diabetic animals supplemented with morin (25 and 50 mg/kg) resulted in a notable decline of blood glucose level at 7, 30, and 60 days.Table 1Notable decline of blood glucose level by morin.**GroupsTreatmentDays073060**INormal Control94.72 ± 2.8797.36 ± 0.7494.49 ± 1.0295.63 ± 1.93IIDiabetic Control95.20 ± 2.51208.59 ± 3.18[\#\#\#](#tblfn1){ref-type="table-fn"}299.26 ± 4.30[\#\#\#](#tblfn1){ref-type="table-fn"}365.74 ± 4.84[\#\#\#](#tblfn1){ref-type="table-fn"}IIIDiabetic + Morin (25 mg/kg)96.04 ± 1.86170.28 ± 2.70[\*\*](#tblfn2){ref-type="table-fn"}210.79 ± 3.17[\*\*](#tblfn2){ref-type="table-fn"}190.68 ± 2.06^\*\*\*^IVDiabetic + Morin (50 mg/kg)95.48 ± 1.80161.38 ± 2.10^\*\*\*^195.41 ± 2.31^\*\*\*^168.53 ± 2.19^\*\*\*^VDiabetic + Metformin (350 mg/kg)94.02 ± 1.21156.25 ± 2.96^\*\*\*^179.73 ± 3.05^\*\*\*^160. 02 ± 2.98^\*\*\*^[^1][^2]

3.2. Endogenous antioxidants, pro-inflammatory cytokines and VEGF content in retina {#s0055}
-----------------------------------------------------------------------------------

We know that endogenous antioxidants are helpful to defend our organs against ROS or oxidative assaults. It protects our biological system from daily exposure of chemicals and heavy metals. During metabolic disorders imbalance between endogenous antioxidants and oxidants promote cellular damage. In the case of antioxidant enzyme activity of retinal tissue, a noteworthy or significant elevation in the LOP level was observed in group II animals. morin (25 and 50 mg/kg) resulted in a notable decline of LPO. Besides, endogenous antioxidant enzymes (GPx, CAT, and SOD) activity were also significantly improved by morin (25 and 50 mg/kg) in a dose-reliant way when compare to group II animals ([Table 2](#t0010){ref-type="table"}).Table 2Noteworthy improvement of endogenous antioxidants in retinal tissue by morin.**GroupsTreatmentLPO (ηm of MDA per mg of protein)GPx (µMole of the oxidized GSH/min/mg of protein)CAT (µm H~2~O~2~/mg of protein)SOD (U/mg of protein)**INormal Control2.18 ± 0.327.91 ± 0.7110.08 ± 0.858.84 ± 0.94IIDiabetic Control10.81 ± 0.96[\#\#\#](#tblfn3){ref-type="table-fn"}2.18 ± 0.26[\#\#\#](#tblfn3){ref-type="table-fn"}3.83 ± 0.98[\#\#\#](#tblfn3){ref-type="table-fn"}1.17 ± 0.29[\#\#\#](#tblfn3){ref-type="table-fn"}IIIDiabetic + Morin (25 mg/kg)6.13 ± 0.64[\*\*](#tblfn4){ref-type="table-fn"}4.08 ± 0.82[\*\*](#tblfn4){ref-type="table-fn"}5.88 ± 0.45[\*\*](#tblfn4){ref-type="table-fn"}4.58 ± 0.90[\*\*](#tblfn4){ref-type="table-fn"}IVDiabetic + Morin (50 mg/kg)2.99 ± 0.61^\*\*\*^7.03 ± 0.75^\*\*\*^8.66 ± 0.90^\*\*\*^7.02 ± 0.81^\*\*\*^VDiabetic + Metformin (350 mg/kg)3.09 ± 0.22^\*\*\*^6.81 ± 0.59^\*\*\*^6.96 ± 0.84^\*\*\*^6.80 ± 0.29^\*\*\*^[^3][^4]

It is well known that increase in cellular markers like inflammatory cytokines and VEGF are responsible for DR. Hence, in the retinal tissue homogenate estimation of those parameters is very essential. From [Table 3](#t0015){ref-type="table"}, we can interpret that diabetic animals of 2nd group (group II) showed a noteworthy or significant elevation of VEGF and inflammatory cytokines (TNF-*α* and IL-1*β*). Inflammatory cytokines and VEGF activity was also notable declined by Morin (25 and 50 mg/kg) in a dose-reliant way when compare to group II animals as shown in [Table 3](#t0015){ref-type="table"}.Table 3Estimation of inflammatory cytokines and VEGF in retinal tissue homogenate.GroupsTreatmentTNF*α* (pg/ml)IL1*β* (pg/ml)VEGF (pg/mg)INormal Control7.99 ± 0.8912.10 ± 0.973.04 ± 0.20IIDiabetic Control57.91 ± 1.63[\#\#\#](#tblfn5){ref-type="table-fn"}66.02 ± 1.69[\#\#\#](#tblfn5){ref-type="table-fn"}7.91 ± 0.78[\#\#\#](#tblfn5){ref-type="table-fn"}IIIDiabetic + Morin (25 mg/kg)34.21 ± 1.02[\*\*\*](#tblfn6){ref-type="table-fn"}37.72 ± 1.80[\*\*\*](#tblfn6){ref-type="table-fn"}4.13 ± 0.61[\*\*\*](#tblfn6){ref-type="table-fn"}IVDiabetic + Morin (50 mg/kg)19.09 ± 1.28[\*\*\*](#tblfn6){ref-type="table-fn"}25.42 ± 1.92[\*\*\*](#tblfn6){ref-type="table-fn"}5.18 ± 0.27[\*\*\*](#tblfn6){ref-type="table-fn"}VDiabetic + Metformin (350 mg/kg)26.15 ± 1.12[\*\*\*](#tblfn6){ref-type="table-fn"}30.04 ± 1.07[\*\*\*](#tblfn6){ref-type="table-fn"}4.87 ± 0.42[\*\*\*](#tblfn6){ref-type="table-fn"}[^5][^6]

3.3. Morphometric analysis {#s0060}
--------------------------

In the morphometric analysis, there was a notable decrease in thickness of the retina. Besides, a noteworthy decrease in quantity of cells in ganglion layer of the animals in group II. A noteworthy improvement was observed in the morin treated groups in a dose-reliant way ([Table 4](#t0020){ref-type="table"}).Table 4Morin improved retinal morphology in diabetic rats.GroupsTreatmentRetinal Thickness (µm)Number of cells in ganglion cell layer/100 µmINormal Control649.82 ± 50.828.45 ± 0.63IIDiabetic Control351.16 ± 41.38[\#\#\#](#tblfn7){ref-type="table-fn"}4.10 ± 0.18[\#\#\#](#tblfn7){ref-type="table-fn"}IIIDiabetic + Morin (25 mg/kg)444.69 ± 46.51[\*\*\*](#tblfn8){ref-type="table-fn"}6.15 ± 0.30[\*\*\*](#tblfn8){ref-type="table-fn"}IVDiabetic + Morin (50 mg/kg)496.90 ± 51.76[\*\*\*](#tblfn8){ref-type="table-fn"}7.19 ± 0.26[\*\*\*](#tblfn8){ref-type="table-fn"}VDiabetic + Metformin (350 mg/kg)478.35 ± 31.62[\*\*\*](#tblfn8){ref-type="table-fn"}6.68 ± 0.86[\*\*\*](#tblfn8){ref-type="table-fn"}[^7][^8]

4. Discussion {#s0065}
=============

STZ is used to induce diabetic conditions in experimental animals. *β*-cells in pancreas contain GLUT2. With help of GLUT2, STZ enter into the *β*-cells, where it alkylates the DNA causes damage or death of *β*-cells ([@b0130]). This study showed a potent antihyperglycemic effect of Morin in STZ-induced type 1 diabetes in a dose-dependent fashion in male Wistar rats, which supports the previously reported antidiabetic activity of morin.

DR is one of the most widely recognized obstacles secondary to diabetes mellitus. An increase in ROS generation induced by high blood glucose levels in diabetic condition act as a pivotal factor in the progression of DR. In this condition, retinal cells are highly at risk to oxidative assaults as it contains a towering amount of fatty acids which are polyunsaturated in nature. A high level of glucose oxidation in retinal cells also aid in the pathogenesis of DR ([@b0030]). In this view, we have observed a notable increment in the LPO level and a noteworthy decrease in endogenous antioxidants (GPx, CAT, and SOD) level. Supplementation with morin significantly reduced LPO and restored the bustle of endogenous antioxidants (GPx, CAT, and SOD). In DR pathogenesis, ROS is mostly engaged ([@b0150], [@b0095]), which appears to be appropriate for the therapeutic interventions, for example, the use of antioxidants from natural sources. Morin is a dietary bioflavonoid that has demonstrated to show potent antioxidant properties in different diabetic models ([@b0005], [@b0020], [@b0025]).

Inflammatory cytokines acts as a pivotal function in progress of both early and late stages of DR. A crucial factor, NF*κβ* is also engaged in upregulation of TNF-*α* and IL-1*β* in turn aid in the advancement of DR ([@b0160]). Several metabolic factors in diabetes, including high production of AGEs and polyols and increased PKC activation activates NF*κβ*. Moreover, it also demonstrated that increased free radicals formation causes oxidative stress and, thus, the activation of NF*κβ*. A study reported that TNF-α and IL-1 accumulate in vitreous fluid of the DR patients ([@b0110]). It is well known that TNF-α is one of the essential inflammatory cytokines which is another crucial factor in proliferation, differentiation, as well as cellular apoptosis ([@b0045]). On the other hand, the presence of IL-1α in vitreous fluid suggests that it might have a role in DR. Further, upregulation of TNF-α can induce adhesion of leukocytes in the retina and BRB collapse ([@b0035], [@b0060]). The influence of this cytokine experimentally demonstrated in TNF-α knockout diabetic mouse where suppression of BRB breakdown suggests the crucial influence of TNF-α BRB breakdown ([@b0060]).

VEGF helps in the progression of the early stage of DR. In diabetes high glucose level increases AGEs which regulates VEGF expression ([@b0135]). Phospholipase C and PKC and Ca^2+^ also promote VEGF induced vascular permeability and neovascularization ([@b0140]). It was discovered that intraocular administration of VEGF in non-diabetic animals elicited abnormalities in retina resemble DR ([@b0010]), which suggests its role in DR. In this study, we found that supplement of Morin remarkably reduced the bustle of TNF-α, IL-1β, and VEGF.

However, in morphometric study, animals of the diabetic control group showed a reduction in the thickness of the retina. Moreover, the decline in the number of cells in the ganglion cell layers diabetic control animals. Treatment with Morin improved both parameters indicates its defensive role against STZ-induced DR in animals.

5. Conclusion {#s0070}
=============

From the above outcome of the experiment we can come to a conclusion that Morin ameliorates DR may be via suppression of cellular markers TNF-α, IL-1β, and VEGF. Besides, Morin also enhanced the thickness of the retina, and the number of cells in the ganglion cell layers. Hence, Morin showed its defensive role against STZ-induced DR in animals.
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